

# 1st Quarter 2020 Results

## 1st Quarter 2020 Sales

Worldwide Increased ▲  
**\$20.7B** | **3.3%**

Excluding acquisitions/  
 divestitures on an  
 operational basis

Worldwide Increased ▲  
**5.6%\***

### Diluted Earnings Per Share

Increased ▲  
**\$2.17** | **56.1%**

### Adjusted Diluted Earnings Per Share\*

Increased ▲  
**\$2.30** | **9.5%**



**Alex Gorsky**  
 Chairman and  
 Chief Executive Officer  
 Johnson & Johnson

“With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic. Johnson & Johnson is built for times like this, and we are leveraging our scientific expertise, operational scale and financial strength in the effort to advance the work on our lead COVID-19 vaccine candidate. We are committed to beginning production at risk imminently and bringing an affordable and accessible vaccine to the public on a not-for-profit basis for emergency pandemic use.”

**\$3.6 Billion**

## Worldwide Consumer Health Sales


Consumer Health worldwide reported sales increased 9.2% or 11.3% operationally<sup>1</sup>. Primary operational contributors:



**\$11.1 Billion**

## Worldwide Pharmaceutical Sales


Pharmaceutical worldwide reported sales increased 8.7% or 10.1% operationally<sup>1</sup>. Primary operational contributors:



**\$5.9 Billion**

## Worldwide Medical Devices Sales

Medical Devices worldwide reported sales decreased (8.2)% or (6.9)% operationally<sup>1</sup>. Primary operational contributors:



Note: values may have been rounded

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson’s earnings release issued on April 14, 2020, available at <http://www.investor.jnj.com/sales-earnings.cfm>.

\*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

<sup>1</sup>Non-GAAP measure; excludes the impact of translational currency.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned to not rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson earnings release issued on April 14, 2020, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.